Group items tagged

AstraZeneca has made its social-media pitch to the FDA. In response to the agency's call for comments on new rules for online marketing and communications, the drugmaker outlined some ways interactions with customers--and potential customers--might be governed. Read more: http://www.fiercepharma.com/story/az-pitches-social-media-rules-fda/2010-03-02?utm_medium=nl&utm_source=internal#ixzz0h2feB1qq

Segasist Technologies, a MaRS Discovery District Client, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Prostate Auto-Contouring software 'Segasist P-AC'.

Interest is booming in the use of mobile devices such as Apple's iPhone for image viewing applications. But that excitement may be dampened somewhat with a recent U.S. Food and Drug Administration (FDA) decision to classify an iPhone image viewing application as a class III device requiring premarket approval.

The week of October 3, 2011,  Segasist Technologies, a MaRS client and tenant will launch its' new cancer diagnostic tool Reconcillio at the American Society for Radiation Oncology conference. Reconcillio is Segasist Technologies' third product and is awaiting FDA approvals.